Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | FAAH | O00519 | 1/20 | 0.57 |
| ▸ | GOT1 | P17174 | 1/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CCR2 | P41597 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2294074 | 0.87 | RAB9A (0.77) | LMNAHTTMAPTGAATRPV1 | |
| SCHEMBL30986029 | 0.86 | RAB9A (0.76) | LMNAHTTMAPTGAATRPV1 | |
| SCHEMBL29185308 | 0.86 | S1PR2 (0.51) | LMNAHTTMAPTGAA | |
| SCHEMBL8098770 | 0.86 | LMNA (0.57) | LMNAHTTMAPTGAATRPV1 | |
| SCHEMBL2384223 | 0.84 | POLB (0.61) | LMNAHTTMAPTGAATRPV1 | |
| SCHEMBL4302538 | 0.84 | LMNA (0.72) | LMNAHTTMAPTGAATRPV1 | |
| SCHEMBL19745233 | 0.84 | RAB9A (0.64) | LMNAHTTMAPTGAATRPV1 | |
| SCHEMBL6764534 | 0.83 | NAMPT (0.61) | MAPTTRPV1FAAHEPHX2 | |
| SCHEMBL7445763 | 0.81 | LMNA (0.69) | LMNAMAPTGAAMEN1KMT2A | |
| SCHEMBL5912834 | 0.81 | EPHX2 (0.60) | LMNAHTTMAPTGAATRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190300-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2011-08-04 | — | — | US | disclosed |
| EP-2164326-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | Euro-Celtique, S.A. (LU) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008150447-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190300-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | CACNA1E, CACNA1B, CACNA1S | LMNA 2476/4885HTT 2426/4885MAPT 2931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.